You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
MK III Upper Extremity ExoskeletonSBC: Ekso Bionics Inc Topic: 739552
As the carry and protective gear of the modern war fighter increases, the burden on the human body will necessarily increase. In our present TALOS MkIII project, we are developing lower body augmentation to preserve speed and agility while bearing this weight. Yet we cannot ignore the impact of this weight on the upper body: in this project we propose to develop an upper body exoskeleton with p ...STTR Phase II 2015 Department of DefenseSpecial Operations Command
Data Driven Intent Recognition FrameworkSBC: OTHER LAB, INC. Topic: NSF13599
A critical aspect of exoskeleton control that has to date introduced a performance limitation is the ability of the exoskeleton to recognize the intent of the operator so it can apply assistance to their desired motion. This intent recognition effort is typically solved using ad-hoc methods where subject matter experts make design decisions and tune transitions to identify intended maneuvers as re ...STTR Phase II 2016 Department of DefenseSpecial Operations Command
Information SalienceSBC: DISCERNING TECHNOLOGIES, LLC Topic: OSD11TD1
Empirical-based mathematical framework and computer algorithms, for representing human perception and cognition processes and limitations, which influence the recognition of salient information about rapidly changing events.STTR Phase II 2015 Department of DefenseOffice of the Secretary of Defense
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care ApplicationsSBC: GeneCapture, Inc. Topic: CBD15C001
The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust moleculaSTTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense